Alzheimer's Disease
Alzheimer's disease is the slow — and so far unstoppable — erasure of a person. It methodically destroys [[how-memory-works|memory]] first, then language, then judgment, then the most basic ability to function — stripping capacities in roughly the reverse order they were acquired in childhood, and it eventually kills — a process that typically takes four to eight years from diagnosis but can stretch to twenty — making it one of the most personally devastating and feared diseases of [[how-aging-works|aging]]. Roughly 55 million people worldwide live with some form of [[dementia|dementia]], and Alzheimer's accounts for most — roughly 60 to 70 percent — of them. There is no known cure, despite decades of research and billions of dollars spent. The disease was first formally described by [[alois-alzheimer|Alois Alzheimer]] in 1906, after he examined the brain of [[auguste-deter|Auguste Deter]], a 51-year-old woman who had died following years of progressive memory loss, and under the microscope he found the now-famous two defining hallmarks of the disease: plaques — clumps of [[amyloid-beta|amyloid-beta]] protein between neurons — and tangles — twisted [[tau-protein|tau]] fibers inside them — that have been studied for over a century but remain frustratingly central to the still-unresolved puzzle of how Alzheimer's actually destroys the [[how-your-brain-works|brain]].
The Amyloid Hypothesis
The amyloid hypothesis has dominated Alzheimer's research for more than three decades, shaping funding priorities, pharmaceutical strategy, and the careers of thousands of scientists. It proposes that the progressive buildup of a specific protein — [[amyloid-beta|amyloid-beta]], which accumulates as sticky plaques between neurons — is the primary driver of the disease, triggering inflammation, [[tau-protein|tau]] tangles, cell death, and cognitive decline in a single devastating cascade. Genetics offered powerful support: mutations in three genes that increase amyloid production cause early-onset familial Alzheimer's, a rare form that can strike as early as the thirties, and the seemingly irrefutable conclusion that removing amyloid should stop the disease drove billions of dollars in massive and ultimately disappointing investment in drug development. Nearly all of it failed — over 200 clinical trials targeting amyloid were conducted between 2000 and 2025, producing almost nothing. Drugs that successfully cleared plaques from the brain — including [[lecanemab|lecanemab]], approved in 2023 — often produced no clinically meaningful improvement in memory; lecanemab showed a statistically significant but modest 27 percent slowing of decline over 18 months, raising the question of whether such a small benefit justifies the cost and risk. The hypothesis may be partly correct, but its dominance has arguably delayed serious exploration of other potentially more fruitful approaches, including [[tau-protein|tau]] propagation, [[neuroinflammation|neuroinflammation]], vascular dysfunction, and metabolic failure — areas that may each play an equally important role and deserve far more attention than the amyloid-centric funding landscape has allowed.
The Silent Phase
The disease begins silently, decades before symptoms appear — amyloid plaques can be detected in the brain 15 to 20 years before the first memory complaints. By the time a person is formally diagnosed, substantial — often irreversible — brain damage has already occurred, with the [[hippocampus|hippocampus]], critical for memory formation, having lost as much as 25 percent of its volume. This long hidden phase is both the disease's cruelty and its most promising potential vulnerability, because if early treatment could begin before symptoms appear — during the years when pathology is building but the brain is still [[neuroplasticity|compensating]] — the outcome might be fundamentally different, a possibility that has launched a new generation of prevention trials. The risk is shaped by both genes — the [[apoe-e4|APOE e4]] allele is the strongest genetic factor, with one copy roughly tripling risk and two copies increasing it 8 to 12 fold — and modifiable lifestyle choices. The broader implication is striking — a significant — roughly 40 percent, according to the [[lancet-commission|Lancet Commission]] on Dementia Prevention — share of cases might be entirely preventable through public health interventions targeting hearing loss, hypertension, obesity, smoking, depression, and physical inactivity — a finding that challenges the long-held assumption that Alzheimer's is purely a matter of inevitable biological fate.
The Human Cost
The true human cost dwarfs the already grim statistics, and the questions the disease raises — about personhood, autonomy, and the right to decide when treatment should stop — have no easy answers. Alzheimer's is virtually unique among terminal diseases in its sheer duration and its relentless, identity-dissolving burden on caregivers — who provide an estimated 18 billion hours of unpaid care per year in the [[united-states|United States]] alone, and the immense financial toll — exceeding $350 billion annually in the United States and over $1.3 trillion globally — is an enormous and growing burden on already-strained health systems and families. Research continues into [[tau-protein|tau]]-targeting therapies, [[neuroinflammation|neuroinflammation]] modulators, [[gene-therapy|gene therapies]], and blood-based [[biomarker|biomarkers]] for early detection — new and more diverse approaches, but as the failure of the amyloid-first strategy has shown, the disease remains one of medicine's most formidable — and most ethically complex and deeply personal — challenges, a reality that [[terry-pratchett|Terry Pratchett]], diagnosed with a variant in 2007, understood as well as anyone before his death in 2015.